Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
The approval clears the way for a US study at leading clinical centers to evaluate the safety and effectiveness of VDYNE’s system in patients
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
